These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 22700000)

  • 1. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
    Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
    J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
    DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
    J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
    Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
    Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
    DuBois SG; Chesler L; Groshen S; Hawkins R; Goodarzian F; Shimada H; Yanik G; Tagen M; Stewart C; Mosse YP; Maris JM; Tsao-Wei D; Marachelian A; Villablanca JG; Matthay KK
    Clin Cancer Res; 2012 May; 18(9):2679-86. PubMed ID: 22421195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
    George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
    Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
    Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
    J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II clinical trial of high-dose [
    Kuroda R; Wakabayashi H; Araki R; Inaki A; Nishimura R; Ikawa Y; Yoshimura K; Murayama T; Imai Y; Funasaka T; Wada T; Kinuya S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1574-1583. PubMed ID: 34837510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
    Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
    Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
    Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
    Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.